XXXX presenting as telangectasias: response to rituximab and combination chemotherapy.

@entity1 @entity2225 @entity706
BACKGROUND: @entity706 is a rare and aggressive disease with abnormal lymphocytes confined within blood vessels. Cutaneous findings are common in the presentation of this disease. OBJECTIVES: The objectives of this article are (1) to describe a case of @entity706 treated with chemotherapy and rituximab and (2) to review the literature with respect to skin findings and outcomes of these @entity1 after chemotherapy. @entity1 : Our @entity1 had an unusual presentation of @entity706 characterized by tender, slightly indurated plaques composed of dense telangectatic vessels. RESULTS: Our @entity1 responded to combination chemotherapy with the addition of a partial course of rituximab (anti- @entity2225 monoclonal antibody). CONCLUSION: @entity706 commonly presents with skin findings of tender indurated plaques and nodules. Although a number of clinical variations exist, telangectatic plaques are rarely described. Including our case, 50 @entity1 have been reported after treatment with chemotherapy. Approximately 46% of treated @entity1 exhibit either partial or complete response to chemotherapy. This is the first reported case of @entity706 treated successfully with the addition of rituximab. Overall, this malignancy remains an unusual and aggressive disease. Recognition of the cutaneous findings and early treatment with chemotherapy may alter the course of this disease. Rituximab may be an important addition to combination chemotherapy in treating @entity706 .
